OsteoArticular Sepsis in Intensive Care unitS
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Oct 3, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients who have severe infections in their joints or bones, specifically those with artificial joints like knee or hip prostheses, who have been admitted to intensive care. The main goals of the study are to understand how these patients are treated during their hospital stay, track their progress, and look at their chances of recovery over two years. Researchers will also examine the types of germs causing these infections and how resistant they are to treatment. This research is being conducted in hospitals across France.
To be eligible for the study, participants must be at least 18 years old and have stayed in intensive care for at least 48 hours with a diagnosis of a joint or bone infection. Importantly, they must not oppose participating in the study. If someone joins, their health information will be collected over two years, which may involve a phone call to check on their condition. This study aims to provide valuable insights that could improve the care and outcomes for patients facing these serious infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient at least 18 years old.
- • Hospitalization in critical care (intensive care unit or continuing care unit) between 2018 and 2022 of at least 48 hours, with prosthetic joint infection (hip, knee or shoulder prosthesis infection) as the main or associated diagnosis.
- Exclusion Criteria:
- • Infection on osteosynthesis material
- • Infection on spinal equipment
- • Patient with several infected prostheses
- • Recurrence of infection on prosthesis with the same microorganism
- • Patient opposing data collection
- • Patient under legal protection.
- • Pregnant or breast-feeding patient.
- • Patient deprived of liberty.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Carine PARE
Study Director
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported